Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03703271 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 214 to 70v8 Show 4 more changesShow less
    • Primary and study completion dates: Dec 31, 2023 to Dec 31, 2026
    • Primary endpoint revised
    • Secondary endpoints: 6 to 7
    • Study description expanded, about 1 word
  2. Primary completion date: Dec 31, 2021 to Dec 31, 2023
    • Study completion date: Dec 31, 2022 to Dec 31, 2023
    v7
  3. Re-verified, no change to tracked fieldsv6
  4. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v5
  5. Start date: Jan 1, 2019 to Mar 1, 2019v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Dec 1, 2018 to Jan 1, 2019v3
  2. Start date: Jan 1, 2019 to Dec 1, 2018
    • Secondary endpoints: details revised at 4 of 6 entries
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study of hysteroscopic repeat curettage as the first-line treatment in low-risk postmolar gestational trophoblastic neoplasia compared with the MTX single drug chemotherapy
Trial Details
NCT Number NCT03703271
Lead Sponsor Women's Hospital School Of Medicine Zhejiang University
Collaborators: Sun Yat-sen University, Huazhong University of Science and Technology, Qilu Hospital of Shandong University
Conditions
(from sponsor)		 Gestational Trophoblastic Neoplasia
Related terms Gestational Trophoblastic Disease
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov